You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for New Drug Application (NDA): 211913


✉ Email this page to a colleague

« Back to Dashboard


NDA 211913 describes ABSORICA LD, which is a drug marketed by Sun Pharm and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the ABSORICA LD profile page.

The generic ingredient in ABSORICA LD is isotretinoin. There are thirteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the isotretinoin profile page.
Summary for 211913
Tradename:ABSORICA LD
Applicant:Sun Pharm
Ingredient:isotretinoin
Patents:2
Pharmacology for NDA: 211913
Medical Subject Heading (MeSH) Categories for 211913
Dermatologic Agents
Teratogens
Suppliers and Packaging for NDA: 211913
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ABSORICA LD isotretinoin CAPSULE;ORAL 211913 NDA Sun Pharmaceutical Industries, Inc. 10631-002 10631-002-31 3 BLISTER PACK in 1 BOX (10631-002-31) / 10 CAPSULE in 1 BLISTER PACK
ABSORICA LD isotretinoin CAPSULE;ORAL 211913 NDA Sun Pharmaceutical Industries, Inc. 10631-003 10631-003-31 3 BLISTER PACK in 1 BOX (10631-003-31) / 10 CAPSULE in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength8MG
Approval Date:Nov 5, 2019TE:RLD:Yes
Patent:⤷  Start TrialPatent Expiration:Aug 4, 2035Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Start TrialPatent Expiration:May 29, 2035Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength16MG
Approval Date:Nov 5, 2019TE:RLD:Yes
Patent:⤷  Start TrialPatent Expiration:Aug 4, 2035Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links